Conditional biologics in cancer immunotherapy: mechanisms, applications and clinical progress
Аннотация
Nature Reviews Drug Discovery, Published online: 09 November 2026; doi:10.1038/s41573-026-01552-x Conditional biologics (CBs) — protein therapeutics engineered to selectively activate within the tumour microenvironment — have the potential to increase the potency and limit the off-target adverse effects of cancer immunotherapies. This Review describes the design principles and activation mechanisms of CBs, assesses those being investigated in the clinic, and addresses ongoing challenges and future directions for the field.